TRABECTEDINE TEVA 0.25 mg, powder for concentrate for infusion bottle
Active ingredients: Trabectedin
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Powder for concentrate for infusionbottleintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TRABECTEDINE TEVA 0,25 mg, poudre pour solution à diluer pour perfusion
- Pharmaceutical form
- poudre pour solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 3 Oct 2022
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66547080CIP75508680CIP133400955086802Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TRABECTÉDINEpoudre | 0,25 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.